Recursion Pharmaceuticals Inc [NASDAQ: RXRX] loss -6.85% on the last trading session, reaching $24420000.0 price per share at the time.
Recursion Pharmaceuticals Inc represents 399.15 million in outstanding shares, while the company has a total market value of $2.04 billion with the latest information. RXRX stock price has been found in the range of $4.98 to $5.48.
If compared to the average trading volume of 24.42M shares, RXRX reached a trading volume of 46352553 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Recursion Pharmaceuticals Inc [RXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RXRX shares is $6.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RXRX stock is a recommendation set at 2.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Recursion Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on May 22, 2023. While these analysts kept the previous recommendation, Needham raised their target price to Buy. The new note on the price target was released on March 16, 2023, representing the official price target for Recursion Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $20, while KeyBanc Capital Markets analysts kept a Overweight rating on RXRX stock.
The Price to Book ratio for the last quarter was 2.19, with the Price to Cash per share for the same quarter was set at 1.24.
Trading performance analysis for RXRX stock
Recursion Pharmaceuticals Inc [RXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, RXRX shares gained by 14.45% in over the last four-week period, additionally sinking by -28.04% over the last 6 months – not to mention a drop of -25.59% in the past year of trading.
Recursion Pharmaceuticals Inc [RXRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Recursion Pharmaceuticals Inc [RXRX] shares currently have an operating margin of -960.08% and a Gross Margin at -37.97%. Recursion Pharmaceuticals Inc’s Net Margin is presently recorded at -961.32%.
Return on Equity for this stock declined to -61.70%, with Return on Assets sitting at -61.70%.
Recursion Pharmaceuticals Inc [RXRX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Recursion Pharmaceuticals Inc go to 25.10%.
An analysis of Institutional ownership at Recursion Pharmaceuticals Inc [RXRX]
There are presently around $76.14%, or 80.23% of RXRX stock, in the hands of institutional investors. The top three institutional holders of RXRX stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 28.14 million shares, which is approximately 11.6199%. BAILLIE GIFFORD & CO, holding 26.59 million shares of the stock with an approximate value of $$199.42 million in RXRX stocks shares; and BAILLIE GIFFORD & CO, currently with $$161.67 million in RXRX stock with ownership which is approximately 8.9004%.
